Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To assess the antitumor efficacy, as determined by the objective response rate (ORR) of single-agent brentuximab vedotin 1.8 mg/kg administered intravenously (IV) every 3 weeks, in patients with relapsed or refractory classical HL who are considered to be not suitable for SCT or multiagent chemotherapy
Critère d'inclusion
- relapsed or refractory Hodgkin Lymphoma